JMP Securities analyst Jason Butler lowered the firm’s price target on Viridian Therapeutics to $42 from $44 and keeps an Outperform rating on the shares following the Q2 results and business update. The firm continues to anticipate key catalysts in the next 12 months, notably the selection of a lead subcutaneous candidate by year-end and Phase 3 results for VRDN-001 in acute TED in mid-2024, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VRDN:
- Viridian Therapeutics reports Q2 EPS ($1.27), consensus ($1.29)
- VRDN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Viridian Therapeutics files to sell 244K shares of common stock for holders
- Viridian Therapeutics management to meet virtually with Jefferies
- Viridian Therapeutics’ VRDN-001 data may keep enthusiasm in check, says RBC